Treatment Information

Back

Colon Cancer treatment details. Alternative.

Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Leuven
Treatments:AlternativeHospital:Universitair Ziekenhuis Gasthuisberg
Drugs:Journal:Link
Date:Jul 2005

Description:

Patients: This Phase I study involved 14 patients with metastatic solid tumors. Seven patients had primary colorectal cancer, three had soft tissue tumors, and two had pancreatic cancer. Eleven patients were men, and three were women. The median age was 58. All but one patient had received systemic or surgical treatment.

Treatment: The treatment consisted of one alternative therapy agent: aviscumine. Aviscumine is a recombinant protein similar to mistletoe lectin-1 and has shown therapeutic potential in preclinical studies.

Toxicity: Grade 3-4 toxicities included increased liver enzymes, hypokalemia, and fatigue.

Results: The median overall survival was not reported. While no evidence of antitumor activity was observed (i.e. responses), the authors noted how some patients achieved stable disease.

Support: Viscum AG financially supported this study, and several authors have worked for this company. Viscum AG manufactures and markets aviscumine.

Correspondence: Patrick Schoffski, MD




Back